The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
Research and Practice in Thrombosis and Haemostasis (RPTH) shared a post on LinkedIn about a recent article by Deepa Gautam, adding:
“Are all platelets the same?
Or are we missing critical biology hiding in plain sight?
We still rely on platelet count and MPV in both research and the clinic.
But this study shows that platelets are far from uniform and that heterogeneity systematically shifts across disease states.
Here’s what this paper delivers.
Using a 12-marker spectral flow cytometry panel pus high – dimensional clustering (PlateletProfiler), the authors map platelet states at single – cell resolution.
Platelets exist along an activation continuum, not just ‘resting vs activated’:
- Resting
- Primed
- Aggregatory
- Procoagulant
Disease reshapes platelet composition across models:
- Inflammation (LPS) – expansion of primed plus aggregatory platelets
- Jak2V617F (MPN) – increase in aggregatory plus procoagulant platelets
- Cancer – enrichment of procoagulant platelets
Key mechanistic signal, all models showed:
- Increased reticulated (young) platelets
- Upregulation of activation plus immune markers (e.g., PD-L1, CD154)
This suggests:
- Accelerated thrombopoiesis
- Functionally ‘pre-activated’ circulating platelets
- A link between platelet biology and immune modulation
Why this matters
We’ve been treating platelets as a homogeneous population.
This framework opens the door to:
- Subpopulation-specific biomarkers
- More precise antiplatelet strategies
- Better mechanistic links between platelets, inflammation, and cancer”
Title: Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis
Authors: Deepa Gautam, Emily M. Clarke, Rebecca L. Zon, Margaret R. Smith-Oliver, Avinash Kumar 5, Megan E. Sullivan, Panagiotis Karagiannis, Harvey G. Roweth, Elisabeth Battinelli
Read the Full Article on RPTH

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation